Will Elevidys Receive Approval from the European Medicines Agency (EMA)? Patients with Duchenne muscular dystrophy (DMD) around Europe are anxiously awaiting the EMA's approval of Sarepta's application for its gene treatment Elevidys. Will Elevidys Receive Approval from the European Medicines Agency (EMA)? 📌 In Which Countries Is Elevidys Approved? 📌 In Which Countries Has Roche Applied for Authorization for Elevidys? 📌 Interim Results from Elevidys’ Embark Clinical Trial Could Impact Decision 📌 Why Are Sarepta and Roche Only Applying for Registration in Certain Countries? 📌 Families Concern if Sarepta for a Different Gene Therapy Will Not Be Approved by EMA 📌 Genethon and Sarepta Collaborated in 2017 📌 Pricing Policies Should Be Revised

Will Elevidys Receive Approval from the European Medicines Agency (EMA)?

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneheroes #musculardystrophy #gene #dna #roche @roche #elevidys #sarepta

Roche Announces New Results from the EMBARK Study of Elevidys in Outpatients with Duchenne Muscular Dystrophy (DMD) Today, Roche revealed encouraging topline data from the second year of the EMBARK trial, a worldwide, double-blind, randomised phase III investigation of Elevidys (delandistrogene moxeparvovec), the first gene therapy to be authorized for the treatment of Duchenne muscular dystrophy. When compared to a predetermined propensity-weighted untreated external control group, statistically significant and clinically meaningful improvements were seen in three important motor function tests two years following Elevidys treatment: NSAA, TTR, and 10MWR. Between one and two years following dose, the functional differences between those receiving Elevidys and those in the external control group grew. When taken as a whole, these findings show that Elevidys has consistently benefited.

Roche Announces New Results from the EMBARK Study of Elevidys in Outpatients with Duchenne Muscular Dystrophy (DMD)

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennesmusculardystrophy #gene #dna #brazil #roche @roche #elevidys #sarepta

dmd warrior dmdwarrior

WE WILL FIGHT DUCHENNE and WE WILL WIN 💪

👉 dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna

Belief BioMed Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate BBM-D101 The U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for Belief BioMed’s (BBM) Duchenne Muscular Dystrophy (DMD) gene therapy candidate, BBM-D101. BBM is a forward-thinking biotechnology company that focuses on creating innovative gene therapies.

Belief BioMed Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate BBM-D101

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #gene #dna #beliefbiomed #BBMD101 #china #shanghai

FDA Grants Rare Pediatric Disease Designation to Nippon Shinyaku’s Exon 51 Skipping Study (NS-051/NCNP-04) Nippon Shinyaku declared that NS-051/NCNP-04, a medication being developed to treat Duchenne Muscular Dystrophy (DMD), has been granted Rare Pediatric Disease Designation by the Food and Drug Administration (FDA). Nippon Shinyaku and the National Center of Neurology and Psychiatry jointly discovered the antisense oligonucleotide NS-051/NCNP-04. By omitting a portion of the dystrophin gene’s genetic material, NS-051/NCNP-04 creates a functioning dystrophin protein with a little shorter chain length, which should prevent the decline in muscle function.

FDA Grants Rare Pediatric Disease Designation to Nippon Shinyaku’s Exon 51 Skipping Study (NS-051/NCNP-04)

👉 Learn More: dmdwarrior.com

#dmd #duchenne #bmd #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #exon51 #exon51skipping #nipponshinyaku #exonskipping

What is Bobcat mRNA? How Does Bobcat mRNA Work for Duchenne Muscular Dystrophy? What is Bobcat mRNA? Bobcat mRNA is a proprietary linear mRNA technology that produces high-quality mRNA encoding large proteins (greater than 13 kb) in a highly efficient and cost-effective manner. A lipid nanoparticle (LNP) delivers it. Elixirgen Therapeutics is first looking into how Bobcat mRNA can be used with dystrophin, which is the largest human gene known.

What is Bobcat mRNA? How Does Bobcat mRNA Work for Duchenne Muscular Dystrophy?

👉 Learn More: dmdwarrior.com

#dmd #duchenne #bmd #becker
#genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneheroes #musculardystrophy #gene #dna #bobcat #mrna #bobcatmrna

Insmed’s Gene Therapy (INS1201) Poised to Challenge Duchenne Muscular Dystrophy (DMD) For its INS1201 Duchenne (DMD) gene therapy, Insmed intends to initiate Phase I clinical trials in the first part of the year 2025. Insmed is getting ready to use its ground-breaking gene therapy, INS1201, to combat Duchenne muscular dystrophy. Insmed intends to start Phase I clinical trials for INS1201 in the first half of 2025 after the FDA approved its investigational new drug (IND) application in December 2024. What is Insmed INS1201 Gene Therapy? Learn More: dmdwarrior.com

Insmed’s Gene Therapy (INS1201) Poised to Challenge Duchenne Muscular Dystrophy (DMD)

👉 Learn More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneheroes #musculardystrophy #gene #dna #insmed #ins1201

Solid Biosciences Releases Information on Clinical Trial for SGT-003 Gene Therapy Solid Biosciences shared detailed information about the clinical trials of its SGT-003 Gene Therapy developed for the treatment of Duchenne Muscular Dystrophy. Solid Biosciences shared that four patients have been dosed in the SGT-003 gene therapy clinical trial; it was well tolerated in all patients with no side effects observed; and data from the first three patients could be available in Q1 2025.

Solid Biosciences Releases Information on Clinical Trial for SGT-003 Gene Therapy

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneawareness #gene #dna #solidbiosciences #sgt003

NICE Final Guidance for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Is Positive for Santhera AGAMREE (vamorolone) has been recommended for use in the National Health Service (NHS) in England, Wales, and Northern Ireland for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 and up by the National Institute for Health and Care Excellence (NICE), according to Santhera Pharmaceuticals.

NICE Final Guidance for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Is Positive for Santhera

👉 Read More: dmdwarrior.com

#dmd #duchenne #dmdwarrior #dmdwarriors #duchennesmusculardystrophy #agamree #vamorolone #santhera #NICE #uk #england #wales #northernireland

ImmunoForge Receives FDA IND Approval for Phase 2 Clinical Trial of ‘Pemziviptadil’ for DMD Cardiomyopathy The U.S. Food and Drug Administration (FDA) has approved ImmunoForge's Phase 2 clinical trial IND for "Pemziviptadil (development code name PF1804)," a treatment for DMD (Duchenne Muscular Dystrophy) cardiomyopathy. A medication for DMD cardiomyopathy, pemziviptadil is used once a week and is based on ImmunForge’s ELP Platform (Elastin Like Polypeptide Platform), a long-acting pharmacological platform. In order to improve cardiac function, pemziviptadil, a vasoactive intestinal peptide (VIP), preferentially works on the vasoactive intestinal peptide receptor 2 (VPAC2) to promote heart contraction and relaxation.

ImmunoForge Receives FDA IND Approval for Phase 2 Clinical Trial of ‘Pemziviptadil’ for DMD Cardiomyopathy

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennesmusculardystrophy #musculardystrophy #gene #dna #ImmunoForge #Pemziviptadil #pf1804

Vamorolone (Agamree) Approved in Scotland The Scottish Medicines Consortium (SMC) approved the Agamree (Vamorolone) for use by NHS Scotland. The medication vamorolone, also marketed under the brand name Agamree, has been approved by the Scottish Medicines Consortium (SMC) as a therapy option for Duchenne muscular dystrophy in patients four years of age and older in Scotland as of today, Monday, January 13 2025.

Vamorolone (Agamree) Approved in Scotland

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna #agamree #vamorolone #santhera #scotland #uk #england

Plans for DYNE-101 in DM1 and DYNE-251 in DMD Are Announced by Dyne Therapeutics Dyne Therapeutics announces clinical trial plans for DYNE-101 and DYNE-251, targeting myotonic dystrophy and Duchenne muscular dystrophy. Dyne Therapeutics announced positive clinical data for its therapies DYNE-101 and DYNE-251 during an investor event on January 10, 2025. DYNE-101 for myotonic dystrophy type 1 (DM1) demonstrated significant splicing correction and functional improvements, leading Dyne to plan a global Registrational Expansion Cohort of the ACHIEVE trial with a registrational dose of 6.8 mg/kg Q8W and a potential U.S. Accelerated Approval submission in H1 2026. Meanwhile, DYNE-251, targeting Duchenne muscular dystrophy (DMD), is also pursuing U.S. Accelerated Approval based on dystrophin as a surrogate endpoint, with data expected by late 2025 to support an early 2026 submission. Both programs show promise in transforming treatment paradigms for these genetic diseases.

Plans for DYNE-101 in DM1 and DYNE-251 in DMD Are Announced by Dyne Therapeutics

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneheroes #musculardystrophy #gene #dna #dyne #dyne251 #dyne101

Nippon Shinyaku Releases First Clinical Trial (First in Human) of Brogidirsen NS-089/NCNP-02 for the Treatment of Duchenne Nippon Shinyaku Corporation has announced the first human trial results of its drug 'Brogidirsen' (NS-089/NCNP-02), which was developed for exon 44 skipping in the treatment of Duchenne muscular dystrophy (DMD). The National Center of Neurology and Psychiatry is announced the publication of a research paper in Cell Reports Medicine detailing the results of an investigator-initiated trial for NS-089/NCNP-02, known as “brogidirsen.” This innovative treatment for Duchenne muscular dystrophy (DMD), jointly developed with Nippon Shinyaku Co., Ltd., represents a significant advancement in exon 44 skipping therapy. What is Brogidirsen? Brogidirsen (NS-089/NCNP-02) is a nucleic acid drug co-discovered by Nippon Shinyaku and NCNP, and is expected to be a therapeutic drug for DMD patients with dystrophin gene mutations amenable to exon 44 skipping.

Nippon Shinyaku Releases First Clinical Trial (First in Human) of Brogidirsen NS-089/NCNP-02 for the Treatment of Duchenne

What is Brogidirsen?

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #nipponshinyaku #brogidirsen #NS089 #exonskipping #exon44

Avidity Biosciences Prepares for Three Rare Muscle Disease Programs’ 2025 BLA Submission and Commercialization Avidity Biosciences, Inc., a biopharmaceutical company producing Antibody Oligonucleotide Conjugates (AOC) RNA therapies, announced its progress and goals for a transformative 2025. A biopharmaceutical firm dedicated to developing a novel class of RNA treatments known as Antibody Oligonucleotide Conjugates (AOCsTM), Avidity Biosciences, Inc., today reported its advancements and plans for a game-changing year in 2025. These significant expected milestones include completing three potentially registrational programs, submitting a Biologics License Application (BLA) for delpacibart zotadirsen (del-zota) for individuals with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44), getting ready for several product launches in DMD44, myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD), and establishing a completely integrated, international business to support an expanding AOC pipeline in precision cardiology and neuromuscular diseases.

Avidity Biosciences Prepares for Three Rare Muscle Disease Programs’ 2025 BLA Submission and Commercialization

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennesmusculardystrophy #duchenne #gene #dna #avidity #aviditybiosciences #raredisease

Turkish DMD Patients Who are Eligible for Exon 51 Skipping Treatment Request Their Medications from the Ministry of Health 🇹🇷 According to the information sent to DMD Warrior by DMD Dayanisma Community, it was understood that Eteplirsen (Exondys 51) was included in the scope of payment by the Ministry of Health in the official response given to the written question submitted by Talih Ozcan, a member of parliament in Turkey, regarding the diagnosis, treatment and social rights of Duchenne Muscular Dystrophy (DMD) patients. According to the DMD Dayanisma Community, patients who are eligible for Exon 51 skipping treatment are not aware that they can get their medication from the Ministry of Health because official associations in Turkey have not made any announcements on their websites about this issue.

Turkish DMD Patients Who are Eligible for Exon 51 Skipping Treatment Request Their Medications from the Ministry of Health 🇹🇷

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #dmdwarrior #dmdwarriors #eteplirsen #ataluren #exondys51 #sarepta #turkish #turkey

Percheron Disappointed in Avicursen (ATL1102) Study For Duchenne (DMD) Percheron plans to broaden pipeline following Avicursen (ATL1102) disappointment. After disappointing Phase IIb results for avicursen last month, Percheron will adopt a three-pronged business strategy. Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides Duchenne muscular dystrophy (DMD) following disappointing Phase IIb results last month. In a letter to shareholders published today (6 January), the chair of the board Dr Charmaine Gittleson, alongside non-executive director Dr Gil Price and managing director Dr James Garner, told shareholders that the company “will undertake a broad strategic review of the company’s pipeline to more comprehensively evaluate alternative sources of value within the current assets”. The review follows negative topline results from the Phase IIb trial (NCT05938023) of avicursen in boys with non-ambulatory DMD. Announced on 18 December, the results demonstrated that the trial did not meet its primary endpoint, which was the Performance of the Upper Limb 2.0 (PUL2.0) score at week 25 compared to placebo.

Percheron Disappointed in Avicursen (ATL1102) Study For Duchenne (DMD)

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennesmusculardystrophy #duchenne #musculardystrophy #percheron #avicursen #atl1102 #NCT05938023 #percherontherapeutics

Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group "We look forward to working with Santhera to make AGAMREE available to patients globally on an unlicensed basis in those territories where it is not currently licensed or reimbursed. ” said Julie Gosper, Senior Vice President, Europe and Partner Markets at Clinigen. Santhera Pharmaceuticals announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) in countries where the product is not otherwise commercially available. Santhera Pharmaceuticals and Clinigen Group announce that they have signed a Supply and Distribution Agreement for AGAMREE in countries where the product can currently not be commercially obtained via Santhera or one of its current distribution partners. The agreement will enable access to AGAMREE on a case-by-case basis for patients with Duchenne muscular dystrophy (DMD) in situations where the treating physician deems there to be no suitable alternatives and where regulations allow for it. This agreement allows Santhera to receive the majority share of revenue generated from the supply of product in these additional countries.

Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #agamree #vamorolone #santhera #Clinigen #clinigengroup

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy What other new gene therapy studies are there besides Elevidys? Let’s remember the new gene therapies that will be an alternative to Elevidys.

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

What other new gene therapy studies are there besides Elevidys?

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchenne #newgenetherapies

One day our children will be able to enjoy life freely. dmd warrior. dmdwarrior.

One day our children will be able to enjoy life freely.

Together, we are stronger. 💪

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #musculardystrophy #gene #dna #newyear #snowboarding #2025 #skiing #world #followme

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy -If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy. -BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku.

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchenne #musculardystrophy #Capricor #Deramiocel #fda

Duchenne Muscular Dystrophy: Treatment & Cost - DMD Warrior Learn about Duchenne Muscular Dystrophy (DMD), its early symptoms, current cures and treatment cost, gene therapies and the future of patients in the World.

Duchenne Muscular Dystrophy: Treatment & Cost

👉 Read and Share: dmdwarrior.com/duchenne-mus...

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchenne #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna #elevidys #exonskipping #exon

Is Duchenne Gene Therapy a Suitable Treatment Despite its Immunogenic Class Effect? This article will examine current gene therapies up to August 2024, including micro-dystrophin Duchenne therapies and CRISPR-Cas9 therapies found on ClinicalTrials.gov. Progressive muscle weakness and eventual mortality as a result of cardiomyopathy or respiratory complications are the hallmarks of Duchenne muscular dystrophy (DMD), a severe X-linked disorder. At present, there is no cure for DMD, and the primary focus of standard treatments is on symptom management. Gene therapies can more effectively address the genetic cause of the disease by employing immunosuppressive measures and optimized vector designs. What are the effects of gene therapy treatments in Duchenne muscular dystrophy (DMD) disease, do gene therapies work? Here is a comprehensive analysis.

Is Duchenne Gene Therapy a Suitable Treatment Despite its Immunogenic Class Effect?

Read More: dmdwarrior.com/is-duchenne-...

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchenne #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna

New Research on Duchenne Muscular Dystrophy Protein Interactions Lead to More Targeted Therapies Study results explain how dystrophin works molecularly, revealing how muscular dystrophy medicines can be developed. A pioneering discovery has shown the complicated relationships between dystrophin, a muscle stability protein, and its companion protein, dystrobrevin, opening new avenues for studying and treating Duchenne Muscular Dystrophy. Researchers describe dystrophin cryptic C-terminal (CT) region and its role in maintaining cellular membranes across tissues in the December Journal of Biological Chemistry. “This research highlights the intricate dynamics of dystrophin and dystrobrevin interactions, providing critical insights that could inform future treatment development,” said study lead author Krishna Mallela, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences professor. Our understanding of how these proteins work in diverse tissues is one step closer to finding DMD treatments that target the root causes.

New Research on Duchenne Muscular Dystrophy Protein Interactions Lead to More Targeted Therapies

Read More: dmdwarrior.com/new-research...

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchenne #musculardystrophy #gene #dna #dystrophin #dystrobrevin

As we step into this new year, we want to send all our love and warmest wishes to you. May this year bring moments of joy, hope, and strength, no matter the challenges you may face. You are so brave, and your spirit inspires everyone around you. To the family: Your love, care, and support mean the world, and together, you make an incredible team. May the year ahead be filled with laughter, treasured memories, and new milestones, no matter how small they may seem. Keep believing in the power of hope and never forget how strong you are as a family. Here's to a year of courage, love, and endless possibilities. Together, we are stronger. 💪 With love and hope, dmdwarrior.com

As we step into this new year, we want to send all our love and warmest wishes to you. May this year bring moments of joy, hope, and strength, no matter the challenges you may face. You are so brave, and your spirit inspires everyone around you. To the family: Your love, care, and support mean the world, and together, you make an incredible team. May the year ahead be filled with laughter, treasured memories, and new milestones, no matter how small they may seem. Keep believing in the power of hope and never forget how strong you are as a family. Here's to a year of courage, love, and endless possibilities. Together, we are stronger. 💪 With love and hope, dmdwarrior.com

As we step into this new year, we want to send all our love and warmest wishes to you. May this year bring moments of joy, hope, and strength, no matter the challenges you may face. You are so brave, and your spirit inspires everyone around you. To the family: Your love, care, and support mean the world, and together, you make an incredible team. May the year ahead be filled with laughter, treasured memories, and new milestones, no matter how small they may seem. Keep believing in the power of hope and never forget how strong you are as a family. Here's to a year of courage, love, and endless possibilities. Together, we are stronger. 💪 With love and hope, dmdwarrior.com

As we step into this new year, we want to send all our love and warmest wishes to you. May this year bring moments of joy, hope, and strength, no matter the challenges you may face. You are so brave, and your spirit inspires everyone around you. To the family: Your love, care, and support mean the world, and together, you make an incredible team. May the year ahead be filled with laughter, treasured memories, and new milestones, no matter how small they may seem. Keep believing in the power of hope and never forget how strong you are as a family. Here's to a year of courage, love, and endless possibilities. Together, we are stronger. 💪 With love and hope, dmdwarrior.com

Together, we are stronger. 💪

Happy New Year
dmdwarrior.com❤️

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchenne #duchenneheroes #musculardystrophy #gene #dna #newyear #happynewyear #2025 #christmas #world #followme

Zebrafish Modeling Shows Promise in Duchenne (DMD) Research Zebrafish (Danio rerio) has emerged as a valuable model organism for investigating musculoskeletal development and the pathophysiology of associated diseases. Key genes and biological processes in zebrafish are very similar to those in humans, and the rapid development and transparent embryos make zebrafish ideal for in vivo studies of bone and muscle formation as well as the molecular mechanisms underlying musculoskeletal disorders. Research is focusing on the utility of zebrafish in modeling various musculoskeletal disorders, with particular emphasis on bone diseases such as osteoporosis and osteogenesis imperfecta, and muscle disorders such as Duchenne muscular dystrophy.

Zebrafish Modeling Shows Promise in Duchenne (DMD) Research

Read More: dmdwarrior.com/zebrafish-mo...

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchenne #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna #zebrafish #crispr #crisprcas9

dmdwarrior dmd warrior

WE WILL FIGHT DUCHENNE and WE WILL WIN 💪

👉 dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna

No one cares about your child as much as you do. Together, we are stronger. 💪 dmd warrior

No one cares about your child as much as you do. Together, we are stronger. 💪

#dmd #duchenne #bmd #becker
#genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna

University of Miami Health System and Holtz Children’s Hospital Physicians Evaluated the Effectiveness of ELEVIDYS University of Miami Health System and Holtz Children’s Hospital physicians are playing a major role in getting ELEVIDYS access. The therapy delivers a functional micro-gene to muscle cells, potentially arresting DMD progression and, in some cases, possibly reversing it. Raniya was the first female ever treated with ELEVIDYS. Siblings Raniya, who is 15 years old, and Amir, 8, received their single ELEVIDYS infusions at Holtz Children’s Hospital in late October. They may have to wait several months to learn if the treatment was successful, but early signs are encouraging. “At her recent appointment, Raniya was already doing better, feeling stronger, walking more and not relying on a wheelchair as much,” said Dr. Lopez-Alberola.

University of Miami Health System and Holtz Children’s Hospital Physicians Evaluated the Effectiveness of ELEVIDYS

Read More: dmdwarrior.com/university-o...

#dmd #duchenne #bmd #becker
#genetherapy #dmdwarrior #dmdwarriors #elevidys #sarepta

SPLICER Gene Editing Tool Holds A Lot of Potential to Treat Duchenne Muscular Dystrophy A new gene editing tool that helps cellular machinery skip parts of genes responsible for diseases has been applied to reduce the formation of amyloid-beta plaque precursors in a mouse model of Alzheimer’s disease, researchers at the University of Illinois Urbana-Champaign report. SPLICER uses a gene editing approach called exon skipping, which is of particular interest for health conditions caused by mutations that produce misfolded or toxic proteins, such as Duchenne’s muscular dystrophy or Huntington’s disease. Perez-Pinera a professor of bioengineering said “But for diseases like Alzheimer’s, Parkinson’s, Huntington’s or Duchenne muscular dystrophy, this approach holds a lot of potential. The immediate next step is to look at the safety of removing the targeted exons in these diseases, and make sure we aren’t creating a new protein that is toxic or missing a key function. We would also need to do longer term animal studies and see if the disease progresses over time.”

SPLICER Gene Editing Tool Holds A Lot of Potential to Treat Duchenne Muscular Dystrophy

Read More: dmdwarrior.com/splicer-gene...

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #SPLICER #geneediting

UK Approves Givinostat (Duvyzat) for Duchenne Muscular Dystrophy Treatment

UK Approves Givinostat (Duvyzat) for Duchenne Muscular Dystrophy Treatment

Givinostat conditionally approved to treat patients with Duchenne muscular dystrophy (DMD)

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #givinostat #duvyzat #mhra #uk #england